Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: RESCRIPTOR

« Back to Dashboard
Rescriptor is a drug marketed by Viiv Hlthcare and is included in one NDA. It is available from three suppliers. There is one patent protecting this drug.

This drug has twenty-one patent family members in twenty countries.

The generic ingredient in RESCRIPTOR is delavirdine mesylate. Three suppliers are listed for this compound. Additional details are available on the delavirdine mesylate profile page.

Summary for Tradename: RESCRIPTOR

Patents:1
Applicants:1
NDAs:1
Suppliers: see list3

Clinical Trials for: RESCRIPTOR

Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients
Status: Completed Condition: HIV-1 Infection

A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies
Status: Completed Condition: HIV Infections

A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients
Status: Completed Condition: HIV Infections

A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients
Status: Completed Condition: HIV Infections

A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients
Status: Withdrawn Condition: HIV Infections

Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects
Status: Completed Condition: HIV Infections

The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
Status: Terminated Condition: HIV Infections

Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir
Status: Completed Condition: HIV Infections

Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)
Status: Completed Condition: HIV Infections

A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy
Status: Completed Condition: HIV Infections

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare
RESCRIPTOR
delavirdine mesylate
TABLET;ORAL020705-001Apr 4, 1997RXNo<disabled><disabled>
Viiv Hlthcare
RESCRIPTOR
delavirdine mesylate
TABLET;ORAL020705-002Jul 14, 1999RXYes6,177,101<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: RESCRIPTOR

Country Document Number Publication Date
Hungary0102206Mar 28, 2002
Hong Kong1036417Jul 14, 2006
World Intellectual Property Organization (WIPO)9963970Dec 16, 1999
Spain2277682Jul 16, 2007
Slovenia1083885Apr 30, 2007
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc